BMS188797

Known as: BMS-188797 
An analog of paclitaxel with antineoplastic activity. BMS-188797 binds to and stabilizes the resulting microtubules, thereby inhibiting microtubule… (More)
National Institutes of Health

Topic mentions per year

Topic mentions per year

2000-2005
0120002005

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2006
2006
RATIONALE BMS-188797 is one of several novel taxanes in ongoing clinical development. It has superior activity in experimental… (More)
  • figure 1
  • table 2
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2006
2006
This phase I study investigated the maximum tolerated dose and pharmacokinetics of a 3-weekly administration of BMS-188797, a… (More)
  • table 1
  • table 2
  • figure 1
  • table 3
  • figure 2
Is this relevant?
2005
2005
PURPOSE Preclinical studies show that BMS-188797 has a broad spectrum of antitumor activity in in vitro cytotoxicity assays and… (More)
  • figure 1
  • table 2
  • table 3
  • table 4
  • table 5
Is this relevant?
2004
2004
BACKGROUND The development of synthetic taxanes targets at increasing solubility of the drug, improved clinical efficacy and… (More)
  • table I
  • table II
  • table III
  • figure 1
  • table IV
Is this relevant?
2003
2003
PURPOSE The purpose of this study was to establish the maximum tolerated dose (MTD), dose-limiting toxicities (DLTs), and… (More)
  • table 1
  • table 2
  • table 3
  • figure 1
  • table 4
Is this relevant?
2001
2001
PURPOSE To evaluate the novel taxane analogs, BMS-184476 and BMS-188797, as potential radiosensitizers in vitro and in vivo… (More)
Is this relevant?
2000
2000
Purpose: Two taxane analogs, BMS-184476 and -188797, were evaluated for their in vitro cytotoxicity and in vivo antitumor… (More)
Is this relevant?